Displaying drugs 15176 - 15200 of 15611 in total
Lusvertikimab
Investigational
GXC-301
Investigational
Zinlirvimab
Zinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children).
Investigational
Visugromab
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
4-(1H-IMIDAZOL-1-YL)PHENOL
Experimental
6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
Experimental
2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
Experimental
Indirubin-3'-monoxime
Experimental
Atpenin A5
Experimental
Tioxidazole
Vet approved
Triazolopyridine
Experimental
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Experimental
2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol
Experimental
2-heptyl-4-hydroxyquinoline N-oxide
Experimental
(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE
Experimental
Displaying drugs 15176 - 15200 of 15611 in total